-
JEM: The development of a new mouse model may be the key to developing better HIV therapies
Time of Update: 2021-06-23
Related research results were recently published in the Journal of Experimental Medicine, with the title of the paper "A participant-derived xenograft model of HIV enables long-term evaluation of autologous immunotherapies" .
-
Renfu Class 1 New Drug Propofol Disodium for Injection Approved for Marketing
Time of Update: 2021-06-23
On May 24, the official website of NMPA showed that Renfu’s Class 1 new drug, propofol disodium for injection, was approved for marketing, and the indication was general anesthesia induction .
-
A pharmaceutical company was fined 3 million in the batch number change!
Time of Update: 2021-06-23
The C12012063 batch of poppy husk production ingredients audit form NO: 202012063 has no regulations on the mixing ratio of ingredients and does not comply with the "Drug Production Quality Management" Standardize (Revised in 2010)" Appendix "Chinese Medicine Decoction Pieces" Article 43 (2) and (4) requirements .
-
The number of pharmaceutical representatives of 30 Japanese companies ranks in 2021, the number of pharmaceutical representatives continues to decrease
Time of Update: 2021-06-22
Of course, in the past year, there have been companies that have increased the number of medical representatives, but they are basically more than 20 people, such as Xinglin Pharmaceutical, Otsuka Pharmaceutical, and Towa Pharmaceuticals.
-
2 billion large varieties!
Time of Update: 2021-06-22
Sales of terminal lansoprazole injections in public medical institutions in China (unit: ten thousand yuan)Source: Mi Nei. com, China's public medical institutions terminal competition patternPreviously reviewed companies for Lansoprazole for injectionSource: Mi Nei Net Consistency Evaluation DatabaseLansoprazole injection has been included in the fifth batch of centralized procurement, and the bid will be opened on June 23.
-
Chen Jiafu, deputy general manager of Tongrentang, resigns
Time of Update: 2021-06-22
Chen Jiafu .
Chen Jiafu ceased to be the deputy general manager of the company due to job changes and applied to resign from the position of deputy general manager of the company .
-
Ascent Pharma's Bcl-2 inhibitor APG-2575 obtained clinical trial approval from the U.S. FDA
Time of Update: 2021-06-22
The study is a global multi-center, open, phase Ib/II clinical study, which aims to evaluate the progress of APG-2575 monotherapy in patients with advanced solid tumors, or in combination with CDK4/6 inhibitor palbociclib after treatment with CDK4/6 inhibitors.
-
Another medicine mining alliance is here!
Time of Update: 2021-06-22
Medicine Medicine Medicine Medical institutions should give priority to the use of selected drugs, strictly implement the selected prices, and ensure that the agreed purchase volume is completed .
-
CStone Pharmaceuticals announces joint development of loratinib with Pfizer in ROS1-positive advanced lung cancer
Time of Update: 2021-06-22
Article source: Medical Rubik's Cube InfoOn June 15th, CStone Pharmaceuticals announced that it would cooperate with Pfizer on ROS1-positive advanced non-small cell lung cancer (NSCLC) in Greater China to jointly develop lorlatinib .
-
Jingxin Pharmaceutical Memantine Hydrochloride Sustained Release Capsules Obtained Drug Registration Approval
Time of Update: 2021-06-22
On June 15, Jingxin Pharmaceutical announced that it had recently received the "Drug Registration Certificate" for the chemical drug "Memantine Hydrochloride Sustained Release Capsules" [Specification 28mg] approved and issued by the State Food and Drug Administration .
-
The long-term efficacy was higher than that of Theo-American Aibervi JAK Inhibitor Phase 3 clinical results
Time of Update: 2021-06-22
Note: There are limitations in the original textResources:[1] New Long-Term Efficacy and Safety Analyses Evaluating RINVOQ® (upadacitinib) in Patients with Rheumatoid Arthritis to be Presented at EULAR 2021 Virtual Congress.
com/news/press-releases/new-long-term-efficacy-and-safety-analyses-evaluating-rinvoq-upadacitinib-in-patients-with-rheumatoid-arthritis-to-be-presented-at-eular-2021-virtual-congress.
htm[2] AbbVie to Present Analysis Evaluating Continuous RINVOQ® (upadacitinib) Treatment in Psoriatic Arthritis for More Than One Year at EULAR 2021 Virtual Congress.
com/news/press-releases/abbvie-to-present-analysis-evaluating-continuous-rinvoq-upadacitinib-treatment-in-psoriatic-arthritis-for-more-than-one-year-at-eular-2021-virtual-congress.
-
Sales of 37 medicines suspended in high-risk areas in Guangdong, "yellow code" customers are not allowed to buy medicines in stores
Time of Update: 2021-06-22
The "Notice" requires that drug retail companies in the province further implement the real-name registration and reporting system for drugs in the "Catalog", requiring customers to enter the store to take their temperature and show their health code.
-
Kangtai Bio freeze-dried Haemophilus influenzae type b conjugate vaccine obtained drug registration certificate
Time of Update: 2021-06-22
(hereinafter referred to as "Minhai Biological"), had recently received the "Drug Registration Certificate" issued by the State Drug Administration .
The freeze-dried Haemophilus influenzae type b conjugate vaccine is suitable for children from 2 months old to 5 years old.
-
Puri Pharmaceuticals Pantoprazole Sodium for Injection Receives Health Canada Approval
Time of Update: 2021-06-22
Pantoprazole Sodium for Injection is a selective long-acting proton pump inhibitor .
It is relatively stable under neutral and weak acidic conditions, and is rapidly activated under strong acidic conditions, thereby having better selectivity for H+ and K+-ATPase .
-
Shouxiangu: Gynecological Shiwei Tablets Received Drug Re-registration Approval Notice
Time of Update: 2021-06-22
Since this product has not been produced for a long time, when production is resumed, an application for on-site inspection must be submitted to the Zhejiang Food and Drug Administration.
After on-site inspection and random inspection of a batch of products, it can be marketed .
-
2020 Medical Insurance Statistics Bulletin released!
Time of Update: 2021-06-22
In 2019, the National Medical Insurance Bureau bulletin showed that the hospitalization expense fund within the scope of the employee medical insurance policy paid 85.
In 2019, the National Medical Insurance Bureau bulletin showed that the hospitalization expense fund within the scope of the employee medical insurance policy paid 85.
-
KRAS inhibitor!
Time of Update: 2021-06-22
According to the press release, Jacos Pharmaceuticals will start multi-center clinical trials for tumor patients with non-small cell lung cancer, colorectal cancer and other solid tumors in China and the United States, and plan to start patient enrollment in the second half of 2021 .
-
The vice president of a drug company who drunk driving was taken criminal coercive measures
Time of Update: 2021-06-22
issued a reminder announcement on the criminal compulsory measures taken by the company's deputy general manager for drunk driving .
Li Haibing, the deputy general manager of the company, that he was informed that he may be subject to further criminal compulsory measures due to drunk driving.
-
Yourui Medicine Obtains the Development and Commercialization Rights of VeronaCOPD New Drug in Greater China
Time of Update: 2021-06-22
According to the terms of the agreement, Verona has granted Yourui Medicine the exclusive right to clinical development and commercialization of ensifentrine in Greater China .
Note: The original text has been deletedReference materials:[1] Verona Pharma and Yourui Pharmaceutical announced a strategic cooperation of US$219 million to develop and commercialize Ensifentrine in Greater China.
-
14 over 100 million proprietary Chinese medicine plasters exposed!
Time of Update: 2021-06-22
According to data from Meinenet, the market share of terminal pain relief plasters in physical pharmacies in Chinese cities has maintained steady growth in recent years, with sales exceeding 600 million yuan in 2020 .
